Post-Grant Proceedings

Post-Grant Proceedings

We advise clients on the smartest, most cost-effective ways to challenge or defend issued patents.

Key Contacts

Meet Our Team

Areas of Focus

Expand All Collapse All

WilmerHale Recognized Throughout IAM Patent 1000 Rankings 2020

News

WilmerHale Recognized by LMG Life Sciences at Annual Awards

News

Experience

  • Successfully represented Aegerion (alongside co-counsel) in two inter partes reviews challenging patents covering the approved dosing methods of Juxtapid, a lipid-lowering agent for the treatment of familial hypercholesterolemia.

  • Achieved a victory for patent owner Akamai Technologies against Limelight Networks when the Patent Trial and Appeal Board issued a final written decision finding all instituted claims not invalid.
  • Successfully invalidated all 371 claims of 10 patents asserted against a major consumer products company (later affirmed by the Federal Circuit) in one of the largest inter partes review proceedings ever brought. 

  • WilmerHale secured a total victory, along with co-counsel, for Gilead Sciences when the PTAB denied institution of the tenth straight petition for IPR of patents directed to Gilead’s Hepatitis C products, including the blockbuster drugs Sovaldi, Harvoni and Epclusa. The series of 10 for 10 denials by the PTAB across eight patents is particularly notable because the PTAB’s IPR institution rate for pharmaceutical patents is generally about 60%.

  • On behalf of Unified Patents, achieved a significant victory when the Patent Trial and Appeal Board issued its final written decision invalidating all claims against a patent, assigned to Nonend Inventions N.V., which Nonend asserted in multiple district court cases against a wide range of companies.
  • Also for Unified Patents, used the inter partes review process to successfully challenge all 16 claims of a patent held by Sportbrain Holdings, which had been asserted against more than 140 defendants.

  • Achieved a series of victories, culminating in four successful covered business method reviews, in which the Patent Trial and Appeal Board invalidated 83 of a patent assertion entity’s claims against a group of major financial institutions.
  • For electronic wheelchair developer Permobil, achieved a victory when the Patent Trial and Appeal Board issued final written decisions on two inter partes reviews that declared all challenged claims unpatentable. WilmerHale also successfully convinced the US Court of Appeals for the Federal Circuit to uphold the decisions after the patent owner appealed.

  • Successfully invalidated a patent through an inter partes review on behalf of Becton Dickinson, challenging a patent relating to needle technology. BD filed the proceeding after it was sued for infringement. We obtained a final written decision canceling all the challenged claims, and the litigation subsequently settled on terms favorable to BD during the Federal Circuit appeal.
  • For a Fortune 500 technology company, obtained a significant victory when the Federal Circuit held that three patent claims that we had challenged in an inter partes review adverse to an acoustics company were unpatentable. The patents related to speaker designs that the acoustics company accused our client of infringing.
  • Represented VMware and EMC in a suit, initially filed in the Eastern District of Texas, relating to cloud computing. The plaintiff, a non-practicing entity, alleged infringement of a portfolio of patents by most of the major cloud computing companies. VMware and EMC were the only companies in the first round of defendants to file inter partes reviews. We ultimately convinced the Eastern District of Texas to transfer the case to California, and convinced the Northern District of California to stay the case pending the proceedings. The Patent Trial and Appeal Board subsequently invalidated all challenged claims, and the Federal Circuit affirmed.

Recognition

  • Award Text

    General Patent Litigation Firm of the Year

    LMG Life Sciences

    2019

  • Award Text

    Ranked Tier 1 in PTAB Litigation

    Managing IP

    2019

  • Award Text

    Law Firm of the Year in Patent Law

    U.S. News – Best Lawyers®

    2021

  • The American Lawyer – Named WilmerHale the Law Firm of the Year (2020), was honored as a finalist in the Litigation Department of the Year contest (2018) and as the IP Litigation Department of the Year (2014, 2008), and named a finalist in the IP category six times since the publication first awarded it in 2004.
  • BTI Consulting Group – Named as an IP Litigation Powerhouse in the 2019 BTI Litigation Outlook (2019) and an IP Litigation Standout (2017, 2018). Recognized as the Most-Favored IP Department in the nation, as one of two firms Best at Complex IP Litigation, one of six Go To IP Litigation Firms, and one of five Go To IP Firms for non-litigation IP work in the BTI Intellectual Property Outlook (2015).
  • Chambers USA: America’s Leading Lawyers for Business – Ranked nationally in band one (2011–2020); noted as “outstanding at all levels, combining first-rate technical and legal acumen and great trial skills.” Consistently recognized in the national International Trade: IP (section 337) category (2013–2020) and in regional IP tables for Massachusetts (2003–2020), California (2012–2020), Colorado (2016–2020), New York (2012–2020) and Washington DC (2012–2020).
  • IAM Patent 1000 – Ranked as a leading firm for litigation in the US and UK, and in regional US rankings in California, Colorado, the DC Metro area, Massachusetts and New York (2018–2020).
  • Law360 – Named among top five “go-to” firms for PTAB litigation in a report on the law firms that handled the most cases at PTAB from 2012–2019. 
  • The Legal 500 United States – Named among the top law firms for intellectual property (2011–2020).
  • Lex Machina Patent Trial and Appeal Board Report – Identified as one of two full-service law firms that are most experienced in representing petitioners at the Patent Trial and Appeal Board (2017). 
  • LMG Life Sciences Awards – Received the Impact Case of the Year Award for our work on Enzo Life Sciences v. Roche Molecular Systems and shortlisted for Firm of the Year in the Licensing  & Collaboration, General Patent Litigation, IP, Inter Partes Review, and Government Investigations categories (2020); named as the General Patent Litigation Firm of the Year and Intellectual Property Firm of the Year and shortlisted for the Hatch-Waxman Litigation (Branded) Firm of the Year, Inter Partes Review Firm of the Year and US Life Cycle Firm of the Year (2019); and won the Hatch-Waxman Impact Case of the Year Award for our role in Millennium Pharmaceuticals v. Sandoz (2018).
  • Managing IP – Named as Patent Contentious Firm of the Year for the Northeast region and recognized with the Impact Case of the Year Award for our role in Mission Products Holdings Inc v. Tempnology LLC (2020); named as the US Patent Contentious Firm of the Year or shortlisted for the recognition for nine consecutive years (2011–2019); ranked Tier 1 for PTAB Litigation (2020); listed among the top 10 “Law Firms for Petitioners and Patent Owners in PTAB Proceedings Filed in 2019” and the top 15 “Law Firms at the PTAB 2019 – Petitioners and Respondents Combined.” 
  • Unified Patents – Recognized for achieving a higher IPR institution rate by claim than any other firm in the country (2015).
  • U.S. News - Best Lawyers® – Named Patent Firm of the Year (2021), Biotechnology Law Firm of the Year (2020) and IP Litigation Law Firm of the Year (2018). Honored with first-tier national “Best Law Firm” rankings in Patent Law, Biotechnology Law, IP Litigation and Patent Litigation; and first-tier metropolitan rankings in Washington DC and San Jose for IP Litigation; in Boston for Copyright Law, Patent Law, Patent Litigation, IP Litigation and Trademark Law; in Colorado for Patent Law; and in New York for Biotechnology Law (2013–2020).

Insights & News